- Home
- MPB vs ABUS Comparison
MPB vs ABUS Comparison
Compare MPB & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- ABUS
- Stock Information
- Founded
- MPB 1868
- ABUS 2005
- Country
- MPB United States
- ABUS United States
- Employees
- MPB N/A
- ABUS N/A
- Industry
- MPB Major Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- ABUS Health Care
- Exchange
- MPB Nasdaq
- ABUS Nasdaq
- Market Cap
- MPB 675.9M
- ABUS 711.2M
- IPO Year
- MPB N/A
- ABUS N/A
- Fundamental
- Price
- MPB $29.29
- ABUS $4.38
- Analyst Decision
- MPB Buy
- ABUS Strong Buy
- Analyst Count
- MPB 2
- ABUS 2
- Target Price
- MPB $34.50
- ABUS $5.00
- AVG Volume (30 Days)
- MPB 178.6K
- ABUS 1.4M
- Earning Date
- MPB 10-22-2025
- ABUS 11-05-2025
- Dividend Yield
- MPB 2.74%
- ABUS N/A
- EPS Growth
- MPB N/A
- ABUS N/A
- EPS
- MPB 2.30
- ABUS N/A
- Revenue
- MPB $191,454,000.00
- ABUS $15,416,000.00
- Revenue This Year
- MPB $24.57
- ABUS $138.02
- Revenue Next Year
- MPB $12.23
- ABUS N/A
- P/E Ratio
- MPB $12.68
- ABUS N/A
- Revenue Growth
- MPB 13.34
- ABUS 53.23
- 52 Week Low
- MPB $22.50
- ABUS $2.71
- 52 Week High
- MPB $33.87
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- MPB 48.72
- ABUS 53.11
- Support Level
- MPB $27.95
- ABUS $4.29
- Resistance Level
- MPB $31.75
- ABUS $4.66
- Average True Range (ATR)
- MPB 0.73
- ABUS 0.17
- MACD
- MPB -0.14
- ABUS -0.05
- Stochastic Oscillator
- MPB 39.47
- ABUS 35.06
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.